CN Patent

CN1930135B — 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶

Assigned to F Hoffmann La Roche AG · Expires 2011-12-28 · 14y expired

What this patent protects

本发明公开了用于治疗由P2X 3 或P2X 2/3 受体拮抗剂介导的疾病的化合物和方法，该方法包括对有需要的对象给予有效量的式(I)化合物或者其药学上可接受的盐、溶剂化物或前体药物， 其中D、X、Y、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 和R 8 如本文所定义。

USPTO Abstract

本发明公开了用于治疗由P2X 3 或P2X 2/3 受体拮抗剂介导的疾病的化合物和方法，该方法包括对有需要的对象给予有效量的式(I)化合物或者其药学上可接受的盐、溶剂化物或前体药物， 其中D、X、Y、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 和R 8 如本文所定义。

Drugs covered by this patent

Patent Metadata

Patent number
CN1930135B
Jurisdiction
CN
Classification
—
Expires
2011-12-28
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.